Unlock stock picks and a broker-level newsfeed that powers Wall Street.

OTC Markets EXMKT - Delayed Quote USD

Theraclion SA (TCLIF)

Compare
0.0002
0.0000
(0.00%)
At close: April 14 at 4:00:00 PM EDT
Loading Chart for TCLIF
  • Previous Close 0.0000
  • Open 2.2800
  • Bid --
  • Ask --
  • Day's Range 0.5900 - 0.5900
  • 52 Week Range 0.0002 - 2.2800
  • Volume 100
  • Avg. Volume 0
  • Market Cap (intraday) 19.976M
  • Beta (5Y Monthly) -0.14
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0900
  • Earnings Date Apr 29, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Theraclion SA designs and markets high-tech therapeutic ultrasound equipment. It offers SONOVEIN, a robotic solution for non-invasive echotherapy treatment of varicose veins; ECHOPULSE, a robotic and non-invasive solution for echotherapy treatment of thyroid nodules and breast fibroadenoma; and EPack, a disposable that is installed on the device before treatment and protects the patient's skin and optimizes the image quality. Theraclion SA was incorporated in 2004 and is based in Malakoff, France.

www.theraclion.com

28

Full Time Employees

December 31

Fiscal Year Ends

Recent News: TCLIF

View More

Performance Overview: TCLIF

Trailing total returns as of 4/15/2025, which may include dividends or other distributions. Benchmark is CAC 40 (^FCHI) .

YTD Return

TCLIF
0.00%
CAC 40 (^FCHI)
1.26%

1-Year Return

TCLIF
99.99%
CAC 40 (^FCHI)
9.41%

3-Year Return

TCLIF
99.99%
CAC 40 (^FCHI)
10.60%

5-Year Return

TCLIF
99.99%
CAC 40 (^FCHI)
67.39%

Compare To: TCLIF

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: TCLIF

View More

Valuation Measures

Annual
As of 4/14/2025
  • Market Cap

    7.48M

  • Enterprise Value

    2.63M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -277.68%

  • Return on Assets (ttm)

    -10.36%

  • Return on Equity (ttm)

    -72.43%

  • Revenue (ttm)

    1.28M

  • Net Income Avi to Common (ttm)

    -3.56M

  • Diluted EPS (ttm)

    -0.0900

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    5.9M

  • Total Debt/Equity (mrq)

    240.88%

  • Levered Free Cash Flow (ttm)

    -4.15M

Research Analysis: TCLIF

View More

Company Insights: TCLIF

Research Reports: TCLIF

View More

People Also Watch